Literature DB >> 25338936

Deoxynivalenol (DON) sulfonates as major DON metabolites in rats: from identification to biomarker method development, validation and application.

Heidi E Schwartz-Zimmermann1, Christian Hametner, Veronika Nagl, Veronika Slavik, Wulf-Dieter Moll, Franz Berthiller.   

Abstract

Deoxynivalenol (DON) is a trichothecene mycotoxin regularly occurring in cereals. Rats are often used to study toxicokinetics of DON and related compounds, yet only about 30 % of the administered dose is typically recovered. Recently, it was reported that DON is partly metabolised to previously undetected DON- and deepoxy-DON (DOM) sulfonate in rats and tentative structures were proposed. The present work describes the production and characterisation of DON-, DOM- and DON-3-glucoside (D3G) sulfonates of three different series; the development and validation of liquid chromatography tandem mass spectrometry (LC-MS/MS)-based methods for determination of DON, DOM, D3G and their sulfonates in rat faeces and urine; and application of the methods to samples from a DON and D3G feeding trial with rats. In addition to previously produced DON sulfonates (DONS) 1, 2 and 3, D3G sulfonates 1, 2 and 3; and DOM sulfonates (DOMS) 2 and 3 were synthesised, purified and characterised. The developed methods showed apparent recoveries of all investigated compounds between 68 and 151 % in faeces and between 48 and 113 % in urine. The recovery of DON, D3G and their metabolites from faeces and urine of rats (n = 6) administered in a single dose of 2.0 mg/kg b.w. DON or the equimolar amount of D3G was 75 ± 9 % for the DON group and 68 ± 8 % for the D3G group. DON-, DOM- and D3G sulfonates excreted in faeces accounted for 48 and 47 % of the total amount of administered DON and D3G. Urinary excretion of sulfonates was <1 %. In both treatment groups, DONS 2 was the major metabolite 0-24 h after treatment, whereas DOMS 2 was predominant thereafter. The developed methods can also be used for investigation of DON (conjugate) sulfonate formation in other animal species.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25338936     DOI: 10.1007/s00216-014-8252-3

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  13 in total

Review 1.  Toxicokinetics and metabolism of deoxynivalenol in animals and humans.

Authors:  Yu Sun; Jun Jiang; Peiqiang Mu; Ruqin Lin; Jikai Wen; Yiqun Deng
Journal:  Arch Toxicol       Date:  2022-07-28       Impact factor: 6.168

2.  Deoxynivalenol and its metabolite deepoxy-deoxynivalenol: multi-parameter analysis for the evaluation of cytotoxicity and cellular effects.

Authors:  Alexandra Springler; Sabine Hessenberger; Nicole Reisinger; Corinna Kern; Veronika Nagl; Gerd Schatzmayr; Elisabeth Mayer
Journal:  Mycotoxin Res       Date:  2016-11-05       Impact factor: 3.833

3.  Sex Is a Determinant for Deoxynivalenol Metabolism and Elimination in the Mouse.

Authors:  James J Pestka; Erica S Clark; Heidi E Schwartz-Zimmermann; Franz Berthiller
Journal:  Toxins (Basel)       Date:  2017-08-04       Impact factor: 4.546

4.  Glucuronidation of deoxynivalenol (DON) by different animal species: identification of iso-DON glucuronides and iso-deepoxy-DON glucuronides as novel DON metabolites in pigs, rats, mice, and cows.

Authors:  Heidi E Schwartz-Zimmermann; Christian Hametner; Veronika Nagl; Iris Fiby; Lukas Macheiner; Janine Winkler; Sven Dänicke; Erica Clark; James J Pestka; Franz Berthiller
Journal:  Arch Toxicol       Date:  2017-06-21       Impact factor: 5.153

Review 5.  Do Plant-Bound Masked Mycotoxins Contribute to Toxicity?

Authors:  Silvia W Gratz
Journal:  Toxins (Basel)       Date:  2017-02-28       Impact factor: 4.546

6.  Determination of Deoxynivalenol Biomarkers in Italian Urine Samples.

Authors:  Barbara De Santis; Francesca Debegnach; Brunella Miano; Giorgio Moretti; Elisa Sonego; Antonio Chiaretti; Danilo Buonsenso; Carlo Brera
Journal:  Toxins (Basel)       Date:  2019-07-25       Impact factor: 4.546

7.  Risk Assessment of Deoxynivalenol by Revisiting Its Bioavailability in Pig and Rat Models to Establish Which Is More Suitable.

Authors:  Manuel Jimmy Saint-Cyr; Agnès Perrin-Guyomard; Jacqueline Manceau; Paméla Houée; Jean-Michel Delmas; Jean-Guy Rolland; Michel Laurentie
Journal:  Toxins (Basel)       Date:  2015-12-01       Impact factor: 4.546

8.  Microbial biotransformation of DON: molecular basis for reduced toxicity.

Authors:  Alix Pierron; Sabria Mimoun; Leticia S Murate; Nicolas Loiseau; Yannick Lippi; Ana-Paula F L Bracarense; Gerd Schatzmayr; Jian Wei He; Ting Zhou; Wulf-Dieter Moll; Isabelle P Oswald
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

9.  Early Activation of MAPK p44/42 Is Partially Involved in DON-Induced Disruption of the Intestinal Barrier Function and Tight Junction Network.

Authors:  Alexandra Springler; Sabine Hessenberger; Gerd Schatzmayr; Elisabeth Mayer
Journal:  Toxins (Basel)       Date:  2016-09-08       Impact factor: 4.546

10.  Metabolism of deoxynivalenol and deepoxy-deoxynivalenol in broiler chickens, pullets, roosters and turkeys.

Authors:  Heidi E Schwartz-Zimmermann; Philipp Fruhmann; Sven Dänicke; Gerlinde Wiesenberger; Sylvia Caha; Julia Weber; Franz Berthiller
Journal:  Toxins (Basel)       Date:  2015-11-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.